Skip to main content

Breadcrumb

  1. Home

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

NTRK Fusions and Trk Proteins: What are They and How to Test for Them

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about NTRK Fusions and Trk Proteins: What are They and How to Test for Them

A solid variant of splenic mesothelial cyst, a case report with molecular analysis

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about A solid variant of splenic mesothelial cyst, a case report with molecular analysis

Radiogenomic analysis of locally advanced lung cancer based on CT imaging and intratreatment changes in cell-free DNA

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Radiogenomic analysis of locally advanced lung cancer based on CT imaging and intratreatment changes in cell-free DNA

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms

Liquid biopsies for residual disease and recurrence

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid biopsies for residual disease and recurrence

Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study

Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Page 86
  • Page 87
  • Page 88
  • Page 89
  • …
  • Next page Next
  • Last page Last
Subscribe to